Pharma Mar, S.A. (LON:0RC6)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 1.46B +29.1% |
| Revenue (ttm) | 196.84M +28.3% |
| Net Income | 70.26M +304.9% |
| EPS | 4.05 |
| Shares Out | n/a |
| PE Ratio | 20.81 |
| Forward PE | 22.08 |
| Dividend | 0.68 (0.67%) |
| Ex-Dividend Date | Jun 25, 2025 |
| Volume | 687 |
| Average Volume | 9,725 |
| Open | 97.90 |
| Previous Close | 97.48 |
| Day's Range | 96.35 - 99.65 |
| 52-Week Range | 70.20 - 105.40 |
| Beta | 0.37 |
| RSI | 51.82 |
| Earnings Date | Apr 29, 2026 |
About Pharma Mar
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to... [Read more]
Financial Performance
In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.
Financial numbers in EUR Financial StatementsNews
Pharma Mar initiated with a Buy at BTIG
BTIG initiated coverage of Pharma Mar (PHMMF) with a Buy rating and EUR 121 price target The current valuation is anchored by a “profitable, cash-generative commercial base” driven by Zepzelca’s
Pharma Mar Earnings Call Transcript: Q4 2025
2025 saw 27% revenue growth, a fivefold EBITDA increase, and major milestones for Zepzelca, including U.S. first-line approval. Strong cash flow and pipeline progress position the company for further growth in 2026.
Pharma Mar Earnings Call Transcript: Q2 2025
Revenues grew 18% year-over-year, driven by strong oncology sales and major licensing deals. EBITDA reached EUR 25 million, net profit EUR 19.4 million, and ZEPZELCA saw significant progress in Europe, China, and regulatory filings.
Pharma Mar Transcript: Status Update
IMforte data for lurbinectedin maintenance in small cell lung cancer are seen as practice-changing, offering meaningful survival benefits and manageable toxicity. Rapid adoption is expected in Europe, though future competition from tarlatamab may impact its long-term role.
Pharma Mar Earnings Call Transcript: Q4 2024
Double-digit revenue growth in 2024 was driven by Sapselca and Yondelis, with EBITDA rising to EUR 13 million and net profit to EUR 26.2 million. Positive clinical milestones and strong cash position support future growth, with regulatory submissions and new launches expected in 2025.
Pharma Mar downgraded to Neutral from Outperform at Oddo BHF
Oddo BHF analyst Juan Ros Padilla downgraded Pharma Mar to Neutral from Outperform with a EUR 48 price target
Pharma Mar initiated with a Buy at Chardan
Chardan initiated coverage of Pharma Mar with a Buy rating and EUR 60 price target. The analyst cites the potential of the company’s lead commercial drug, Zepzelca targeting small cell
Pharma Mar Earnings Call Transcript: Q2 2024
H1 2024 saw revenue growth driven by Zepzelca and increased royalties, with strong R&D investment and a robust balance sheet. Key clinical trials are progressing well, and Zepzelca's China approval is anticipated soon, while share buybacks and dividends continue.
Pharma Mar Earnings Call Transcript: Q4 2023
Pharma Mar Earnings Call Transcript: Q3 2023
Pharma Mar Earnings Call Transcript: Q2 2023
Pharma Mar upgraded to Outperform from Neutral at Oddo BHF
Oddo BHF upgraded Pharma Mar to Outperform from Neutral with a EUR 48 price target. The company’s lung cancer drug Zepzelca has a lot of potential and the stock’s current